Tabersonine affects osteoclast differentiation, apoptosis and ameliorates bone loss in osteoporotic mice

This study investigates the effects of tabersonine on osteoclast differentiation, apoptosis, and bone loss in osteoporotic mice. To address these objectives, we performed a series of in vitro and in vivo experiments. In vitro, RAW264.7 cell viability was assessed using the CCK-8 method, and osteoclast-like cells were induced with RANKL. The impact of tabersonine on osteoclast-like cell differentiation was assessed via TRAP staining, while DAPI and TRITC-Phalloidin staining were used to examine nuclear morphology and actin filament organization. Apoptosis in mature osteoclast-like cells was evaluated using Hoechst 33258 staining, and intracellular ROS levels were measured using a commercial assay kit. The expression of genes associated with osteoclast differentiation and apoptosis was analyzed by quantitative real-time PCR, and corresponding protein levels were determined via Western blotting. In vivo, an osteoporosis mouse model was established and treated with tabersonine. The femurs were collected and subjected to micro-CT reconstruction, H&E staining, and TRAP staining to evaluate the extent of bone loss. The results demonstrated that in vitro, tabersonine significantly inhibited osteoclast-like cell differentiation, accompanied by reduced expression of key differentiation-related genes, including MMP-9 and NFATc1, and altered activation of differentiation-associated proteins such as NFATc1, C-Fos, and C-Jun. Furthermore, tabersonine promoted apoptosis in mature osteoclast-like cells, as evidenced by upregulated apoptosis-related genes (Caspase-3 and Bax) and proteins (Caspase-3, Bax, Bcl-2, and Caspase-9). In vivo, tabersonine ameliorated bone loss parameters and reduced osteoclast numbers in femoral tissues of osteoporotic mice. Collectively, these findings suggest that tabersonine suppresses osteoclast-like cell differentiation and facilitates apoptosis of mature osteoclast-like cells, thereby effectively attenuating bone loss in osteoporotic mice.

Authors

Institutions

Publication Details

Journal
European Journal of Histochemistry
Published
2026-11-20
DOI
https://doi.org/10.4081/ejh.2026.4546
Primary Topic
Bone Metabolism and Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tabersonine affects osteoclast differentiation, apoptosis and ameliorates bone loss in osteoporotic mice

王志辉, 仝锡帅, Jingxian Fan, Pinghui Zhou et al.
European Journal of Histochemistry
Bone Metabolism and Diseases
article

Tabersonine affects osteoclast differentiation, apoptosis and ameliorates bone loss in osteoporotic mice

王志辉, 仝锡帅, Jingxian Fan, Pinghui Zhou, Hui Shi, Nan Zhang, Xu Weng, Yingxiao Fu, Chengfeng Xu, Mengying Xu, Shiying Bian, Qin Yang
article en

Abstract

This study investigates the effects of tabersonine on osteoclast differentiation, apoptosis, and bone loss in osteoporotic mice. To address these objectives, we performed a series of in vitro and in vivo experiments. In vitro, RAW264.7 cell viability was assessed using the CCK-8 method, and osteoclast-like cells were induced with RANKL. The impact of tabersonine on osteoclast-like cell differentiation was assessed via TRAP staining, while DAPI and TRITC-Phalloidin staining were used to examine nuclear morphology and actin filament organization. Apoptosis in mature osteoclast-like cells was evaluated using Hoechst 33258 staining, and intracellular ROS levels were measured using a commercial assay kit. The expression of genes associated with osteoclast differentiation and apoptosis was analyzed by quantitative real-time PCR, and corresponding protein levels were determined via Western blotting. In vivo, an osteoporosis mouse model was established and treated with tabersonine. The femurs were collected and subjected to micro-CT reconstruction, H&E staining, and TRAP staining to evaluate the extent of bone loss. The results demonstrated that in vitro, tabersonine significantly inhibited osteoclast-like cell differentiation, accompanied by reduced expression of key differentiation-related genes, including MMP-9 and NFATc1, and altered activation of differentiation-associated proteins such as NFATc1, C-Fos, and C-Jun. Furthermore, tabersonine promoted apoptosis in mature osteoclast-like cells, as evidenced by upregulated apoptosis-related genes (Caspase-3 and Bax) and proteins (Caspase-3, Bax, Bcl-2, and Caspase-9). In vivo, tabersonine ameliorated bone loss parameters and reduced osteoclast numbers in femoral tissues of osteoporotic mice. Collectively, these findings suggest that tabersonine suppresses osteoclast-like cell differentiation and facilitates apoptosis of mature osteoclast-like cells, thereby effectively attenuating bone loss in osteoporotic mice.

European Journal of HistochemistryVol. 70(4)
Bengbu Medical College (CN), Anhui Medical University (CN), Ministry of Education (MV)
Bone Metabolism and Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon